Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes
The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible. Diabetic retinopathy is the mo...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 2017-04, Vol.376 (16), p.1507-1516 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1516 |
---|---|
container_issue | 16 |
container_start_page | 1507 |
container_title | The New England journal of medicine |
container_volume | 376 |
creator | Nathan, David M Bebu, Ionut Hainsworth, Dean Klein, Ronald Tamborlane, William Lorenzi, Gayle Gubitosi-Klug, Rose Lachin, John M |
description | The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible.
Diabetic retinopathy is the most common cause of blindness in adults in the United States.
1
Fortunately, the risk of the development and progression of retinopathy can be reduced substantially by modern-day intensive glycemic management.
2
–
5
Moreover, if clinically significant macular edema or vision-threatening proliferative diabetic retinopathy develops, timely intervention with laser photocoagulation or with intraocular glucocorticoids or anti–vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision.
6
–
9
Thus, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss.
In patients with type 1 diabetes, annual screening for retinopathy starting . . . |
doi_str_mv | 10.1056/NEJMoa1612836 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5557280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4321886129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-2f30b4b2f92058bf7c49dfe2c899cab3810c8f76c4a024f073d0ab03406c7b5d3</originalsourceid><addsrcrecordid>eNp1kd9rFDEQx4Mo9lp99FUCIvRldfJrN_si1Hq1SlXQ-hyy2Umb4zY5k73C_femXC1WcGCYgfnwZb58CXnB4A0D1b79uvz8JVnWMq5F-4gsmBKikRLax2QBwHUju14ckMNSVlCLyf4pOeBaciFALcj5WcZfW4xuR5Ony5sw1h2b97bgSH-4jBhDvKI-Zfod5xDTxs7XOxoivdxtkDL6IdgBZyzPyBNv1wWf380j8vNseXl63lx8-_jp9OSicVKqueFewCAH7nsOSg--c7IfPXKn-97ZQWgGTvuuddIClx46MYIdQFRDrhvUKI7Iu73uZjtMODqMc7Zrs8lhsnlnkg3m4SWGa3OVboxSquMaqsDxnUBO1XmZzRSKw_XaRkzbYpjuGdRuRUVf_YOu0jbHau-WAi6k6lSlmj3lciolo79_hoG5zcg8yKjyL_92cE__CaUCr_fANBUTcTX9R-g3st6XaA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1890234575</pqid></control><display><type>article</type><title>Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine</source><creator>Nathan, David M ; Bebu, Ionut ; Hainsworth, Dean ; Klein, Ronald ; Tamborlane, William ; Lorenzi, Gayle ; Gubitosi-Klug, Rose ; Lachin, John M</creator><creatorcontrib>Nathan, David M ; Bebu, Ionut ; Hainsworth, Dean ; Klein, Ronald ; Tamborlane, William ; Lorenzi, Gayle ; Gubitosi-Klug, Rose ; Lachin, John M ; The DCCT/EDIC Research Group ; DCCT/EDIC Research Group</creatorcontrib><description>The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible.
Diabetic retinopathy is the most common cause of blindness in adults in the United States.
1
Fortunately, the risk of the development and progression of retinopathy can be reduced substantially by modern-day intensive glycemic management.
2
–
5
Moreover, if clinically significant macular edema or vision-threatening proliferative diabetic retinopathy develops, timely intervention with laser photocoagulation or with intraocular glucocorticoids or anti–vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision.
6
–
9
Thus, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss.
In patients with type 1 diabetes, annual screening for retinopathy starting . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1612836</identifier><identifier>PMID: 28423305</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adolescent ; Adult ; Clinical significance ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (insulin dependent) ; Diabetes Mellitus, Type 1 - complications ; Diabetic retinopathy ; Diabetic Retinopathy - diagnosis ; Disease Progression ; Edema ; Epidemiology ; Evidence-Based Medicine ; Eye examinations ; Follow-Up Studies ; Glycated Hemoglobin - analysis ; Hemoglobin ; Humans ; Intervention ; Macular Edema - diagnosis ; Markov Chains ; Medical screening ; Photography ; Practice Guidelines as Topic ; Retina ; Retina - pathology ; Retinopathy ; Risk Factors ; Schedules ; Vascular endothelial growth factor ; Visual Acuity ; Young Adult</subject><ispartof>The New England journal of medicine, 2017-04, Vol.376 (16), p.1507-1516</ispartof><rights>Copyright © 2017 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-2f30b4b2f92058bf7c49dfe2c899cab3810c8f76c4a024f073d0ab03406c7b5d3</citedby><cites>FETCH-LOGICAL-c445t-2f30b4b2f92058bf7c49dfe2c899cab3810c8f76c4a024f073d0ab03406c7b5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1612836$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1612836$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28423305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nathan, David M</creatorcontrib><creatorcontrib>Bebu, Ionut</creatorcontrib><creatorcontrib>Hainsworth, Dean</creatorcontrib><creatorcontrib>Klein, Ronald</creatorcontrib><creatorcontrib>Tamborlane, William</creatorcontrib><creatorcontrib>Lorenzi, Gayle</creatorcontrib><creatorcontrib>Gubitosi-Klug, Rose</creatorcontrib><creatorcontrib>Lachin, John M</creatorcontrib><creatorcontrib>The DCCT/EDIC Research Group</creatorcontrib><creatorcontrib>DCCT/EDIC Research Group</creatorcontrib><title>Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible.
Diabetic retinopathy is the most common cause of blindness in adults in the United States.
1
Fortunately, the risk of the development and progression of retinopathy can be reduced substantially by modern-day intensive glycemic management.
2
–
5
Moreover, if clinically significant macular edema or vision-threatening proliferative diabetic retinopathy develops, timely intervention with laser photocoagulation or with intraocular glucocorticoids or anti–vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision.
6
–
9
Thus, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss.
In patients with type 1 diabetes, annual screening for retinopathy starting . . .</description><subject>Adolescent</subject><subject>Adult</subject><subject>Clinical significance</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Diabetes Mellitus, Type 1 - complications</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - diagnosis</subject><subject>Disease Progression</subject><subject>Edema</subject><subject>Epidemiology</subject><subject>Evidence-Based Medicine</subject><subject>Eye examinations</subject><subject>Follow-Up Studies</subject><subject>Glycated Hemoglobin - analysis</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Intervention</subject><subject>Macular Edema - diagnosis</subject><subject>Markov Chains</subject><subject>Medical screening</subject><subject>Photography</subject><subject>Practice Guidelines as Topic</subject><subject>Retina</subject><subject>Retina - pathology</subject><subject>Retinopathy</subject><subject>Risk Factors</subject><subject>Schedules</subject><subject>Vascular endothelial growth factor</subject><subject>Visual Acuity</subject><subject>Young Adult</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kd9rFDEQx4Mo9lp99FUCIvRldfJrN_si1Hq1SlXQ-hyy2Umb4zY5k73C_femXC1WcGCYgfnwZb58CXnB4A0D1b79uvz8JVnWMq5F-4gsmBKikRLax2QBwHUju14ckMNSVlCLyf4pOeBaciFALcj5WcZfW4xuR5Ony5sw1h2b97bgSH-4jBhDvKI-Zfod5xDTxs7XOxoivdxtkDL6IdgBZyzPyBNv1wWf380j8vNseXl63lx8-_jp9OSicVKqueFewCAH7nsOSg--c7IfPXKn-97ZQWgGTvuuddIClx46MYIdQFRDrhvUKI7Iu73uZjtMODqMc7Zrs8lhsnlnkg3m4SWGa3OVboxSquMaqsDxnUBO1XmZzRSKw_XaRkzbYpjuGdRuRUVf_YOu0jbHau-WAi6k6lSlmj3lciolo79_hoG5zcg8yKjyL_92cE__CaUCr_fANBUTcTX9R-g3st6XaA</recordid><startdate>20170420</startdate><enddate>20170420</enddate><creator>Nathan, David M</creator><creator>Bebu, Ionut</creator><creator>Hainsworth, Dean</creator><creator>Klein, Ronald</creator><creator>Tamborlane, William</creator><creator>Lorenzi, Gayle</creator><creator>Gubitosi-Klug, Rose</creator><creator>Lachin, John M</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170420</creationdate><title>Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes</title><author>Nathan, David M ; Bebu, Ionut ; Hainsworth, Dean ; Klein, Ronald ; Tamborlane, William ; Lorenzi, Gayle ; Gubitosi-Klug, Rose ; Lachin, John M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-2f30b4b2f92058bf7c49dfe2c899cab3810c8f76c4a024f073d0ab03406c7b5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Clinical significance</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Diabetes Mellitus, Type 1 - complications</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - diagnosis</topic><topic>Disease Progression</topic><topic>Edema</topic><topic>Epidemiology</topic><topic>Evidence-Based Medicine</topic><topic>Eye examinations</topic><topic>Follow-Up Studies</topic><topic>Glycated Hemoglobin - analysis</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Intervention</topic><topic>Macular Edema - diagnosis</topic><topic>Markov Chains</topic><topic>Medical screening</topic><topic>Photography</topic><topic>Practice Guidelines as Topic</topic><topic>Retina</topic><topic>Retina - pathology</topic><topic>Retinopathy</topic><topic>Risk Factors</topic><topic>Schedules</topic><topic>Vascular endothelial growth factor</topic><topic>Visual Acuity</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nathan, David M</creatorcontrib><creatorcontrib>Bebu, Ionut</creatorcontrib><creatorcontrib>Hainsworth, Dean</creatorcontrib><creatorcontrib>Klein, Ronald</creatorcontrib><creatorcontrib>Tamborlane, William</creatorcontrib><creatorcontrib>Lorenzi, Gayle</creatorcontrib><creatorcontrib>Gubitosi-Klug, Rose</creatorcontrib><creatorcontrib>Lachin, John M</creatorcontrib><creatorcontrib>The DCCT/EDIC Research Group</creatorcontrib><creatorcontrib>DCCT/EDIC Research Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nathan, David M</au><au>Bebu, Ionut</au><au>Hainsworth, Dean</au><au>Klein, Ronald</au><au>Tamborlane, William</au><au>Lorenzi, Gayle</au><au>Gubitosi-Klug, Rose</au><au>Lachin, John M</au><aucorp>The DCCT/EDIC Research Group</aucorp><aucorp>DCCT/EDIC Research Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2017-04-20</date><risdate>2017</risdate><volume>376</volume><issue>16</issue><spage>1507</spage><epage>1516</epage><pages>1507-1516</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>The probability of progression from “preclinical” diabetic retinopathy to proliferative retinopathy or clinical macular edema was estimated. Individualized screening frequency based on the current retinopathy state and glycated hemoglobin level appeared to be feasible.
Diabetic retinopathy is the most common cause of blindness in adults in the United States.
1
Fortunately, the risk of the development and progression of retinopathy can be reduced substantially by modern-day intensive glycemic management.
2
–
5
Moreover, if clinically significant macular edema or vision-threatening proliferative diabetic retinopathy develops, timely intervention with laser photocoagulation or with intraocular glucocorticoids or anti–vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision.
6
–
9
Thus, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss.
In patients with type 1 diabetes, annual screening for retinopathy starting . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>28423305</pmid><doi>10.1056/NEJMoa1612836</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-4793 |
ispartof | The New England journal of medicine, 2017-04, Vol.376 (16), p.1507-1516 |
issn | 0028-4793 1533-4406 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5557280 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine |
subjects | Adolescent Adult Clinical significance Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 - complications Diabetic retinopathy Diabetic Retinopathy - diagnosis Disease Progression Edema Epidemiology Evidence-Based Medicine Eye examinations Follow-Up Studies Glycated Hemoglobin - analysis Hemoglobin Humans Intervention Macular Edema - diagnosis Markov Chains Medical screening Photography Practice Guidelines as Topic Retina Retina - pathology Retinopathy Risk Factors Schedules Vascular endothelial growth factor Visual Acuity Young Adult |
title | Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A53%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frequency%20of%20Evidence-Based%20Screening%20for%20Retinopathy%20in%20Type%201%20Diabetes&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Nathan,%20David%20M&rft.aucorp=The%20DCCT/EDIC%20Research%20Group&rft.date=2017-04-20&rft.volume=376&rft.issue=16&rft.spage=1507&rft.epage=1516&rft.pages=1507-1516&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1612836&rft_dat=%3Cproquest_pubme%3E4321886129%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1890234575&rft_id=info:pmid/28423305&rfr_iscdi=true |